Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:42:51 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Z:ABBV - ABBVIE INC - http://www.abbvie.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABBV - Z0.5159.28·188.000.1159.62-7.67-4.610,721.51,710,74989,846167.09  167.46  157.65182.89  130.960119:59:3407:3515 min RT 2¢

Recent Trades - Last 10 of 89846
Time ETExPriceChangeVolume
19:59:34Z160.00-7.291
19:59:32Z160.11-7.181
19:59:10Z160.12-7.1796
19:58:55Z159.65-7.6450
19:54:23Z160.12-7.175
19:36:56Z160.00-7.291
19:34:41Z159.99-7.302
19:33:32Z160.00-7.2946
19:22:02Z160.00-7.291
19:21:34Z160.00-7.291

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-26 07:35U:ABBVNews ReleaseAbbVie Reports First-Quarter 2024 Financial Results
2024-04-25 08:00U:ABBVNews ReleaseNew Data Show RINVOQ(TM) (upadacitinib) Demonstrated Superiority Versus DUPIXENT(TM) (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
2024-04-23 08:00U:ABBVNews ReleaseAllergan Aesthetics Invites Consumers to Be the Face of BOTOX(TM) Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
2024-04-18 08:31U:ABBVNews ReleasePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ(TM)) Showed Positive Results in Patients With Giant Cell Arteritis
2024-04-12 07:30U:ABBVNews ReleaseAbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA(TM)) for Preventive Treatment of Migraine
2024-04-09 08:00U:ABBVNews ReleaseSkinMedica(TM) Empowers Clear Skin Confidence with a New, Modern Approach to Acne
2024-04-04 08:00U:ABBVNews ReleaseAbbVie to Host First-Quarter 2024 Earnings Conference Call
2024-04-03 08:30U:ABBVNews ReleaseAllergan Aesthetics Announces the Return of CoolMonth with CoolSculpting(TM)
2024-04-01 07:50U:ABBVNews ReleaseNEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
2024-03-25 11:00U:ABBVNews ReleaseAllergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
2024-03-25 08:31U:ABBVNews ReleaseAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
2024-03-22 15:02U:ABBVNews ReleaseU.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE(TM) (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
2024-03-21 08:00U:ABBVNews ReleaseALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
2024-03-07 08:00U:ABBVNews ReleaseAbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
2024-03-06 08:03U:ABBVNews ReleaseAbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
2024-03-05 08:30U:ABBVNews ReleaseIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
2024-03-05 08:00U:ABBVNews ReleaseJUVEDERM(TM) VOLUMA(TM) XC For Temple Hollows Receives U.S. FDA Approval
2024-03-05 07:00U:ABBVNews ReleaseDragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303